138 related articles for article (PubMed ID: 15284857)
1. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
[No Abstract] [Full Text] [Related]
2. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
Kelaidi C; Rollot F; Park S; Tulliez M; Christoforov B; Calmus Y; Podevin P; Bouscary D; Sogni P; Blanche P; Dreyfus F
Leukemia; 2004 Oct; 18(10):1711-6. PubMed ID: 15284859
[TBL] [Abstract][Full Text] [Related]
3. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
Ignatova TM; Mukhin NA
Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
[TBL] [Abstract][Full Text] [Related]
4. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.
Hermine O; Lefrère F; Bronowicki JP; Mariette X; Jondeau K; Eclache-Saudreau V; Delmas B; Valensi F; Cacoub P; Brechot C; Varet B; Troussard X
N Engl J Med; 2002 Jul; 347(2):89-94. PubMed ID: 12110736
[TBL] [Abstract][Full Text] [Related]
5. Regression of splenic lymphoma after treatment of hepatitis C virus infection.
Emens LA; Sulkowski MS
N Engl J Med; 2002 Dec; 347(26):2168-70; author reply 2168-70. PubMed ID: 12501855
[No Abstract] [Full Text] [Related]
6. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa.
Levine AM; Shimodaira S; Lai MM
N Engl J Med; 2003 Nov; 349(21):2078-9. PubMed ID: 14627800
[No Abstract] [Full Text] [Related]
7. Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin.
Oda Y; Kou T; Watanabe M; Sakuma Y; Taguchi N; Kato Y; Kudo Y; Yamauchi A; Sugiura Y; Ohashi S; Asada M; Fukunaga T; Kawaguchi K; Ito H; Nakamura T; Yazumi S
Dig Dis Sci; 2010 Jun; 55(6):1791-3. PubMed ID: 19657737
[No Abstract] [Full Text] [Related]
8. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Yuen MF; Lai CL
Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis C virus genotype 4: epidemiology and treatment].
Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
[No Abstract] [Full Text] [Related]
10. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
[No Abstract] [Full Text] [Related]
11. Regression of splenic lymphoma after treatment of hepatitis C virus infection.
Mazzaro C; Little D; Pozzato G
N Engl J Med; 2002 Dec; 347(26):2168-70; author reply 2168-70. PubMed ID: 12501232
[No Abstract] [Full Text] [Related]
12. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
13. Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
Mazzaro C; Spina M; Tirelli U
J Clin Oncol; 2005 Jul; 23(19):4470-1; author reply 4471. PubMed ID: 15994165
[No Abstract] [Full Text] [Related]
14. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
15. HCV genotype 5: epidemiology and spread of an uncommon genotype.
Verbeeck J; Peigue-Lafeuille H; Ross RS; Abergel A; Nevens F; Van der Merwe S; Van Ranst M; Henquell C
J Clin Virol; 2008 Feb; 41(2):170-1. PubMed ID: 18069057
[No Abstract] [Full Text] [Related]
16. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with hepatitis C virus on the waiting list.
Everson GT
Liver Transpl; 2003 Nov; 9(11):S90-4. PubMed ID: 14586902
[TBL] [Abstract][Full Text] [Related]
19. HCV-associated lymphomas.
Fiorilli M; Mecucci C; Farci P; Casato M
Rev Clin Exp Hematol; 2003 Dec; 7(4):406-23. PubMed ID: 15129650
[TBL] [Abstract][Full Text] [Related]
20. Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin.
Boulestin A; Sandres-Saune K; Alric L; Pipy B; Dubois M; Vinel JP; Izopet J
Antivir Ther; 2005; 10(4):499-504. PubMed ID: 16038475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
